Clinical Trials

Title   A Single Arm Open-Label Phase IIb Study to Assess the Efficacy and Safety of the Combination of Cediranib and Olaparib Tablets in Women with Recurrent Platinum Resistant Epithelial Ovarian Cancer, Including Fallopian Tube and/or Primary Peritoneal Cancer
Description   This is an open label, single arm, multi-center study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in platinum-resistant relapsed high grade serous, high grade endometroid or clear cell ovarian, fallopian tube or primary peritoneal carcinoma patients who have received at least 3 prior lines of chemotherapy and who do not carry deleterious or suspected deleterious germline breast cancer susceptibility gene (BRCA) mutations.
IRB Number   17-324
Treatment   Oncology - Ovarian Cancer
Status   Active
Start Date   03/05/2018
Principal Name   Rodney Rocconi MD
Contact Name   Kathleen Ollis

Email Newsletters

Connect With Us